Loading…
●Research use only — not for human or veterinary use
A neutral overview of GLP-1 receptor signalling and the incretin system as described in the research literature. This page is educational and intentionally links to no products.
This overview describes mechanisms studied in the scientific literature. It is not medical advice and does not describe clinical use. No catalogue products are linked from this page.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone studied widely in metabolic and endocrine research. This overview summarises how the GLP-1 pathway is described in the scientific literature. It is educational only — it does not describe clinical use, regimens, or outcomes for any individual.
The incretin effect refers to the augmented insulin response observed after oral versus intravenous glucose in research models. GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) are the two principal incretin peptides described in this literature, released from intestinal enteroendocrine cells in response to nutrient sensing.
The GLP-1 receptor is a class B G-protein-coupled receptor. In research models its activation is associated with Gs-coupled adenylate-cyclase activity and downstream cAMP/PKA signalling. Co-agonist and triple-agonist peptides studied in the literature (for example dual GLP-1R/GIPR agonists) are of interest precisely because they engage more than one incretin receptor.
Current literature explores receptor pharmacology, structural biology of agonist binding, and comparative signalling between mono-, dual- and triple-agonist peptides. These are active areas of basic and pre-clinical research.
Research use only — All products and content are intended strictly for in-vitro laboratory research and analytical use. Not for human or veterinary use, not for consumption, and not for any diagnostic or therapeutic purpose.